NASDAQ
COCH
Last Price
US $0.7463
Valuation
Financial
Performance
Cash flow to debt coverage
Envoy Medical, Inc. cash flow to debt ratio of -1.98K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Free cash flow growth
Envoy Medical, Inc.'s free cash flow has increased -2.90% from $-18.93M last year to $-18.38M, signaling increasing performance
Debt-to-equity ratio
Envoy Medical, Inc.'s debt to equity ratio is 0.25, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
Envoy Medical, Inc.'s debt has increased relative to shareholder equity from -1.04 last year to 0.25 today, signaling weakened financials
Net debt to EBITDA
Envoy Medical, Inc. has a net cash position, so leverage is healthy.
Interest coverage
Envoy Medical, Inc.'s interest coverage ratio is -50.15, which means that the company struggles to meet interest obligations, signaling financial risk.
Profit margin growth
Envoy Medical, Inc.'s profit margin has decreased (22.32%) in the last year from -9.24K% to -11.30K%, signaling decreasing performance
Current ratio
Envoy Medical, Inc.'s short-term liabilities of $11.56M exceed its short-term assets of $6.28M, signaling financial risk
Return on assets
Envoy Medical, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Envoy Medical, Inc.'s return on equity of 1.72K%, is higher than 15.00%, indicating good performance
Earnings quality
Envoy Medical, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
Envoy Medical, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings
Positive free cash flow
Envoy Medical, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Envoy Medical, Inc. has negative free cash flow, indicating cash burn
Earnings growth
Envoy Medical, Inc.'s yearly earnings has decreased 14.24% since last year from $-20.80M to $-23.76M, signaling decreasing performance
Revenue growth
Envoy Medical, Inc.'s yearly revenue has increased 7.11% since last year from $225.00K to $241.00K, signaling increasing performance
Return on invested capital
ROIC -206.35% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
Envoy Medical, Inc.'s 3-year revenue CAGR of 0.56% is positive, indicating growing revenue over the past 3 years
Revenue consistency
Envoy Medical, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance
Return on equity consistency
Envoy Medical, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity
Cash Flow Valuation (DCF)
Envoy Medical, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
Envoy Medical, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
EBITDA Valuation
Envoy Medical, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
Envoy Medical, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Envoy Medical, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
Envoy Medical, Inc. has a price-to-book ratio of 22.24x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Price-to-sales ratio (TTM)
Envoy Medical, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
1719.71%
Return on equity
ROIC: -206.35%
Valuation History
-
Price to Earnings
EV/EBITDA: 0.15X
Cash flow
Profit margin
-87.38%
Cash flow
-
Fair Value
Market $0.7463
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.